Climb Bio, Inc. ((CLYM)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Climb Bio, Inc. (CLYM) is currently conducting a Phase 1 study titled A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous and Intravenous Injections of Budoprutug (TNT119) in Normal Healthy Volunteers. The study aims to assess the safety and tolerability of budoprutug injections in healthy volunteers, marking a significant step in the drug’s development.
The intervention being tested is Budoprutug, administered either subcutaneously or intravenously. This drug is designed to evaluate its safety profile and pharmacological effects in humans.
The study employs a randomized, double-blind, placebo-controlled design with a sequential intervention model. Both participants and investigators are masked to ensure unbiased results, focusing on basic scientific understanding.
The study began on July 21, 2025, with its primary completion and estimated overall completion dates yet to be announced. The latest update was submitted on August 15, 2025, indicating active recruitment.
This update could influence Climb Bio’s stock performance positively, as successful early-phase trials often boost investor confidence. However, the competitive landscape in the biotechnology sector means that investors should remain cautious and informed about industry trends.
The study is ongoing, with further details available on the ClinicalTrials portal.